Ischemic Postconditioning in STEMI Patients Treated With Primary PCI

Recruiting now · Not applicable · Has a placebo group

Conditions studied: ST Segment Elevation Myocardial Infarction

In brief

In a prospective, randomized clinical trial the iPOST2 trial will determine whether ischemic postconditioning reduces reperfusion injury and this will translate into improved clinical outcome of heart failure and death for STEMI patients who present with TIMI0-1 undergoing primary PCI

Key facts

Study ID

NCT03787745

Run by

Rigshospitalet, Denmark

People needed

1800

Starts

2019-02-04

Expected to finish

2033-01-31

Last updated by the study team

2026-03-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 years
• Acute onset of chest pain with < 12 hours duration
• STEMI as characterized by 2 mm ST elevation in 2 or more V1 through V4 leads or presumed new left bundle branch block with minimum of 1 mm concordant ST elevation or 1 mV ST-segment elevation in the limb lead (II, III and aVF, I, aVL) and V4-V6 or ST depression in 2 or more V1 through V4 leads indicating posterior AMI.
• TIMI flow 0-1 in infarct related artery

You may not qualify if…

• Potential pregnancy
• Refusal to participate
• OHCA without subsequent consciousness despite ROSC
• Thrombectomy considered unavoidable

Where it is running

• The Heart Center, Rigshospitalet, University of Copenhagen — Copenhagen, Denmark (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.